Senolytics
Intervention6 papers7 findings
In a human trial, dasatinib plus quercetin reduces liver cellular senescence and improves fibrotic metabolic dysfunction-associated steatohepatitis. Other senolytics clear senescent cells in mice and zebrafish, reduce pathogenic CD4+ T cells in mice, and reviews describe fisetin lowering chronic human inflammation.
- Human trial1
- Animals3
- Model organisms1
- Cells1
Outcomes
6Cellular senescence
downin humans1downin mice1
2 studies
Cellular senescence
downin humans1downin mice1
Dasatinib + quercetin decreases cellular senescence in humans.
Human trialfibrotic MASHliverdasatinib 100 mg per day plus quercetin 1,000 mg per daythree consecutive days per week over 3 weeks, repeated across three 7-week cycles
Dasatinib and quercetin reduce liver fibrosis in a phase-2 MASH trial · Nature metabolism · 1 Oct 2026
Senolytics decrease cellular senescence in mice.
AnimalsCyclin D2-p21 double-positive senescent macrophagesliver
A distinct p21-driven macrophage senotype accumulates during aging and liver disease · bioRxiv · 28 Sep 2026 · Preprint
Metabolic dysfunction-associated steatohepatitis
downin humans1
1 study
Metabolic dysfunction-associated steatohepatitis
downin humans1
Dasatinib + quercetin decreases metabolic dysfunction-associated steatohepatitis in humans (-1.43 ± 1.22 versus -0.39 ± 0.77).
Human trialfibrotic MASHliverdasatinib 100 mg per day plus quercetin 1,000 mg per daythree consecutive days per week over 3 weeks, repeated across three 7-week cycles
Dasatinib and quercetin reduce liver fibrosis in a phase-2 MASH trial · Nature metabolism · 1 Oct 2026
Fibrotic metabolic dysfunction-associated steatohepatitis
downin humans1
1 study
Fibrotic metabolic dysfunction-associated steatohepatitis
downin humans1
Dasatinib + quercetin decreases fibrotic metabolic dysfunction-associated steatohepatitis in humans (47% versus 7%).
Human trialfibrotic MASHliverdasatinib 100 mg per day plus quercetin 1,000 mg per daythree consecutive days per week over 3 weeks, repeated across three 7-week cycles
Dasatinib and quercetin reduce liver fibrosis in a phase-2 MASH trial · Nature metabolism · 1 Oct 2026
Senescent cell
downin zebrafish1
1 study
Senescent cell
downin zebrafish1
Navitoclax decreases senescent cell in zebrafish.
Animalsin cells with high UHRF1 levelshepatocyte
UHRF1 levels drive distinct senescent states in zebrafish liver cells · EMBO reports · 28 Sep 2026
Pathogenic capacity of CD4+ T cells
downin mice1
1 study
Pathogenic capacity of CD4+ T cells
downin mice1
Fisetin decreases pathogenic capacity of CD4+ T cells in mice.
AnimalsCD4-positive alpha-beta T cell
Senescent CD4 T cells drive age-associated autoimmunity in mice and humans · bioRxiv : the preprint server for biology · 22 Sep 2026 · Preprint
Chronic inflammation
downin humans1
1 study
Chronic inflammation
downin humans1
Fisetin decreases chronic inflammation in humans.
“While some studies reported favorable changes in metabolic or inflammatory outcomes, others found no clear or significant clinical benefit.”
Reviewin some human clinical trials
Clinical Translation of Fisetin for Age-Related Diseases: Current Evidence and Future Opportunities · Nutrients · 14 Sep 2026
Latest
19Senescent CD4 T cells drive age-associated autoimmunity in mice and humans
Targeting senescent immune cells with fisetin or ruxolitinib reduced disease features and protected mice against autoimmune peripheral nerve damage.
bioRxiv : the preprint server for biology · McCarthy EC et al.
Senescent prostate cancer cells drive stromal remodeling through TGF-beta signaling
Researchers found that senescent epithelial cells secrete TGF-beta1 to reprogram fibroblasts into a matrix-remodeling state, which senolytic treatment can blunt.
Neoplasia (New York, N.Y.) · Lin C et al.
DNA methylation proxies of senescence markers track human disease and mortality
The new blood-based tools estimate senescence gene activity to predict incident diseases, all-cause mortality, and clinical treatment responses.
medRxiv · Simpson DJ et al.
Dasatinib and quercetin reduce liver fibrosis in a phase-2 MASH trial
The senolytic combination improved liver fibrosis without disease worsening in nearly half of treated participants while lowering cellular senescence markers.
Nature metabolism · Koning M et al.
Future directions of osteoanabolic therapies in osteoporosis: Integrating current anabolic agents and emerging senescence-targeted strategies
Crosstalk between exosomes and cellular senescence: A core vicious loop promoting α-synuclein pathology in Parkinson's disease
Ultrasound-activated quantum biomaterial pairs with senolytic to suppress colorectal cancer
Combining pyroptosis-inducing Pd3Sn nanostructures with the senolytic piperlongumine targets treatment-induced senescent cells and reduces metastatic tumor burden in animal models.
Advanced science (Weinheim, Baden-Wurttemberg, Germany) · Chen Z et al.